Skip to content
GLP-1 Desk
Menu
Dispatch #8

Pallas Health

Pallas Health names all six of the pharmacies that dispense for it and two prescribing clinicians whose NPIs verify in the federal registry — then sells every GLP-1 on a single twelve-week prepay, so the advertised “/mo average” is one $597 or $897 charge divided by three.

Visit Pallas Health ↗Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way.
Semaglutide
$199/mo average (compounded injectable; $597 billed every 12 weeks after $139 for the first 4 weeks; no month-to-month tier is sold)
Tirzepatide
$299/mo average (compounded injectable; $897 billed every 12 weeks after $179 for the first 4 weeks; no month-to-month tier is sold)
Coverage
All 50 states + DC (async in 43; 7 states plus DC require one video visit)
Brand-name
Yes

Weigh Pallas Health against the full ranked field on the best semaglutide providers ranking, or line it up against its closest alternatives. Or go one-on-one: Pallas Health vs CoreAge Rx.

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency78/100
State access94/100
Molecule range90/100
Onboarding speed88/100
Support responsiveness88/100
Licensing & trust90/100

What the Desk likes

  • Names all six dispensing pharmacies publicly — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — and explains the 503A/503B distinction beside them; most rows here name none
  • Names two prescribing clinicians with their NPI numbers and links the NPPES registry to check them: Dr. Ana Lisa Carr, MD (family medicine per NPPES, licensed in 15 states) and Dr. Kelly Tenbrink, MD (emergency medicine, Tennessee and Florida). Both verified active in August 2026; a fabricated control NPI returned nothing in the same pass
  • LegitScript Healthcare Merchant Certified, seal ID 49989444, confirmed live against LegitScript's own seal endpoint — three invented control IDs were rejected in the same pass
  • Clean on the FDA warning-letter database in August 2026 across the brand, the operator (Brentmoor, Inc.) and the clinical platform (CareValidate), with a positive control firing in the same pass so the zero is a real absence
  • The marketing price is the checkout price: the homepage FAQ, the landing pages, the treatment pages and the live funnel all state the same four figures, with no step-up appearing at the card form
  • No minimum term — cancel any time from a self-serve portal, effective at the end of the current billing period, with a pre-renewal email before each charge and a published promise of at least 30 days' notice before any price change
  • All 50 states plus DC, fully asynchronous in 43 of them, with free shipping when prescribed, FSA/HSA eligibility per the site banner, and a full refund if a clinician declines you
  • Brand-name Zepbound, Ozempic, Wegovy and Mounjaro are available cash-pay alongside the compounded lines, which most compounded-only desks cannot offer at all

Where points come off

  • There is no month-to-month rung for either compounded molecule — the funnel renders no cadence selector — so the advertised “$199/mo average” is a single $597 charge every twelve weeks divided by three
  • The cash-flow shape is the likeliest surprise: a $139 first payment is followed four weeks later by $597 in one go, and on tirzepatide $179 is followed by $897
  • Twelve weeks is not three months. The charge recurs every 84 days — 4.35 times a year, not 4 — so on Pallas's own published renewal terms the ongoing cost works out at roughly $2,596 a year (about $216/mo) for semaglutide and roughly $3,900 a year (about $325/mo) for tirzepatide, against advertised averages of $199 and $299
  • $139 and $179 are first-period rates covering the opening four weeks only, and the sitewide “Up to $120 off your first month” banner is a discount rather than a price
  • Only two clinicians are named site-wide. The prescribing network behind them — Lion MD's affiliated professional corporations — is not published, and the footer “Provider directory” link resolves to a section naming the same two
  • Pallas itself has no FDA warning letter on the public record, but one of the six pharmacies it names, Belmar, received one issued in March 2023 and addressed to “Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy” — the FDA closed that letter out in October 2023
  • The site's own footer states that some of its content is AI-generated with no representation or warranty as to accuracy, which is reason enough not to cite its blog for a clinical claim
  • The advertised “4.8” rating carries no published source, and the before/after “Verified Customer” stories are captioned that individuals shown may be actors or models
  • Compounded semaglutide and tirzepatide are not FDA-approved and are not generic equivalents of the brand drugs — Pallas discloses this properly, and it stays true whoever discloses it
  • Cash-pay only, no insurance ever: the brand-name lines run $1,069/mo for Zepbound up to $1,349/mo for Wegovy and Mounjaro, far above what an insured patient pays
  • A $60 visit deposit can be retained if you skip or abandon the video visit required in Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and DC, and a $5 fee comes off each refunded payment on purchases from July 2026 — neither applies to a clinician-declined or unfulfilled order, which refund in full
  • Whether baseline or follow-up lab work is included is not published, and there is no pre-purchase dose selector against which to test the flat-price claim

The Desk's briefing — B+

Best for: Readers who weight named pharmacies and independently verifiable prescribers above cash-flow flexibility, and who can absorb a $597 or $897 charge every twelve weeks rather than a monthly one.

Pallas Health ranks #8 of 508 providers scored — see #1, CoreAge Rx here.

Visit Pallas Health ↗

Related dispatches

Everyone else here (19)

Pricing and verification reflect Pallas Health's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Pallas Health's site. Not medical advice; see our disclosure.

← Back to The Desk